...
首页> 外文期刊>Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships >Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas
【24h】

Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas

机译:慢性卡麦角林治疗和睾丸激素替代对男性泌乳素瘤患者代谢的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Hyperprolactinemia and hypogonadism are reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of testosterone replacement and cabergoline (CAB) treatment on the metabolic profile in male hyperprolactinemic patients. Patients and Methods: Thirty-two men with prolactinomas, including 22 with total testosterone (TT) <8 nmol/l (HG, 69%) and 10 with TT >8 nmol/l (non-HG, 31%), were entered in the study. In all patients, metabolic parameters were assessed at diagnosis and after 12- and 24-month treatment. Results: Compared to non-HG patients, at baseline the HG patients had higher waist circumference (WC). TT significantly correlated with body mass index (BMI). Twelve-month CAB induced PRL normalization in 84%. HG prevalence significantly decreased (28%) and non-HG prevalence significantly increased (72%). Anthropometric and lipid parameters, fasting insulin (FI), insulin sensitivity index (ISI0), homeostatic model assessment of insulin secretion (HOMA-beta) and homeostatic model assessment of insulin resistance (HOMA-IR) significantly improved compared to baseline. TT was the best predictor for FI. Percent change (Delta) of TT significantly correlated with Delta Cholesterol, Delta Weight and Delta BMI. Compared to non-HG patients, the HG patients had a higher weight, BMI, WC and HOMA-beta. In HG, testosterone replacement was started. After 24 months, PRL normalized in 97%. HG prevalence significantly decreased (6%) and non-HG prevalence significantly increased (94%). Anthropometric and lipid parameters, FI, ISI0, HOMA-beta and HOMA-IR significantly improved compared to baseline, with FI, ISI0, HOMA-beta and HOMA-IR further ameliorating compared to the 12-month evaluation. Compared to non-HG patients, the HG patients still had a higher weight, BMI and WC. Conclusions: In hyperprolactinemic hypogonal men, proper testosterone replacement induces a significant improvement in the metabolic profile, even though the amelioration in the lipid profile might reflect the direct action of CAB. (C) 2015 S. Karger AG, Basel
机译:简介:据报道,高催乳素血症和性腺功能低下与代谢状况受损有关。当前的研究旨在调查睾丸激素替代和卡麦角林(CAB)治疗对男性高泌乳素血症患者代谢谱的影响。患者和方法:输入了32例泌乳素瘤男性,其中22例总睾酮(TT)<8 nmol / l(HG,69%)和10例TT> 8 nmol / l(非HG,31%)在研究中。在所有患者中,在诊断时以及治疗12个月和24个月后评估代谢参数。结果:与非HG患者相比,基线时HG患者的腰围(WC)更高。 TT与体重指数(BMI)显着相关。十二个月的CAB诱导PRL正常化的比例为84%。 HG患病率显着降低(28%),非HG患病率显着增加(72%)。与基线相比,人体测量学和脂质参数,空腹胰岛素(FI),胰岛素敏感性指数(ISI0),胰岛素分泌稳态模型评估(HOMA-beta)和胰岛素抵抗稳态模型评估(HOMA-IR)。 TT是FI的最佳预测指标。 TT的百分比变化(Delta)与Delta胆固醇,Delta重量和Delta BMI显着相关。与非HG患者相比,HG患者的体重,BMI,WC和HOMA-beta更高。在HG中,开始更换睾丸激素。 24个月后,PRL恢复正常,为97%。 HG患病率显着降低(6%),非HG患病率显着提高(94%)。与基线相比,人体测量和血脂参数FI,ISI0,HOMA-beta和HOMA-IR显着改善,而FI,ISI0,HOMA-beta和HOMA-IR与12个月评估相比进一步改善。与非HG患者相比,HG患者的体重,BMI和WC更高。结论:在泌乳激素过多的性腺机能减退的男性中,适当的睾丸激素替代可改善代谢状况,即使脂质状况的改善可能反映了CAB的直接作用。 (C)2015 S.Karger AG,巴塞尔

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号